Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity
Resumen: Transthyretin (TTR) is a plasma homotetrameric protein implicated in fatal systemic amyloidoses. TTR tetramer dissociation precedes pathological TTR aggregation. Native state stabilizers are promising drugs to treat TTR amyloidoses. Here we repurpose tolcapone, an FDA-approved molecule for Parkinson''s disease, as a potent TTR aggregation inhibitor. Tolcapone binds specifically to TTR in human plasma, stabilizes the native tetramer in vivo in mice and humans and inhibits TTR cytotoxicity. Crystal structures of tolcapone bound to wild-type TTR and to the V122I cardiomyopathy-associated variant show that it docks better into the TTR T4 pocket than tafamidis, so far the only drug on the market to treat TTR amyloidoses. These data indicate that tolcapone, already in clinical trials for familial amyloid polyneuropathy, is a strong candidate for therapeutic intervention in these diseases, including those affecting the central nervous system, for which no small-molecule therapy exists.
Idioma: Inglés
DOI: 10.1038/ncomms10787
Año: 2016
Publicado en: Nature Communications 7 (2016), 10787 [13 pp]
ISSN: 2041-1723

Factor impacto JCR: 12.124 (2016)
Categ. JCR: MULTIDISCIPLINARY SCIENCES rank: 3 / 63 = 0.048 (2016) - Q1 - T1
Factor impacto SCIMAGO: 6.413 - Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q1) - Physics and Astronomy (miscellaneous) (Q1) - Chemistry (miscellaneous) (Q1)

Financiación: info:eu-repo/grantAgreement/ES/MICINN/BFU2010-19451
Financiación: info:eu-repo/grantAgreement/ES/MINECO/BFU2013-47064-P
Financiación: info:eu-repo/grantAgreement/EUR/SUDOE/INTERREG IV B/SOE4-P1-E831
Tipo y forma: Article (Published version)
Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)
Exportado de SIDERAL (2020-02-21-13:07:20)

Este artículo se encuentra en las siguientes colecciones:

 Notice créée le 2016-04-08, modifiée le 2020-02-21

Versión publicada:
Évaluer ce document:

Rate this document:
(Pas encore évalué)